Program Slides Download (PDF)
A recent paradigm shift has resulted in an expanded role for surgical oncologists within the multidisciplinary cancer care team for basal cell carcinoma (BCC). Thus, these clinicians need additional education on all recent therapeutic advances in the management of BCC. It is crucial that surgical oncologists be kept up to date on the mechanisms of action of novel agents, as well as their roles in improving surgical outcomes for patients with BCC and incorporating patient selection criteria, dosing strategies, and side-effect management. This program will help surgical oncologists understand the role of multimodality therapies in the management of BCC, and will allow them to incorporate recent evidence-based therapeutic regimens into their clinical practices, ultimately leading to improved patient outcomes.
This presentation was selected by the Society of Surgical Oncology as an independent educational activity held at the site of the 2014 Annual Cancer Symposium. This presentation is not sponsored or endorsed by the Society of Surgical Oncology.
Sanjiv S. Agarwala, MD
Associate Professor of Cancer Biology
University of Pennsylvania
Chief, Oncology and Hematology
St. Luke's Cancer Center
Merrick Ross, MD
Charles M. McBride Distinguished Professorship in Surgical Oncology
Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Aleksandar Sekulic, MD, PhD
Assistant Professor of Dermatology
Mayo Clinic in Arizona
This program is intended for surgical oncologists, medical oncologists, radiation oncologists, dermatologists, and other health care professionals who are involved in the care of patients with basal cell carcinoma.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Assess multimodality treatment options for patients with advanced BCC
- Discuss integration of updated clinical practice guidelines for BCC into practice
- Review efficacy and safety data for novel treatment agents for BCC
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Method of Participation
To receive continuing medical education (CME) and MOC Part II certification credit, participants must view the content, successfully complete the self-assessment exam and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the corresponding rationale. Learners will be able to review the content and repeat the self-assessment exam as many times needed. Upon achieving a score of 75% or higher on all of the modules, learners will be asked to complete a post-activity evaluation. A CME/MOC certificate will be sent via e-mail upon successful submission of the post-activity evaluation.
There is no fee for this program.
ESTIMATED TIME TO COMPLETE ACTIVITY
The estimated time to complete this entire activity is 1 hour.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Maintenance of Certification (MOC) Credit is only for surgeons who are involved in the treatment of patients with cancer. The Potomac Center for Medical Education under the American Board of Surgery MOC Criteria has approved this activity for up to 1 MOC Part II certification points.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Sanjiv S. Agarwala, MD – Speaker: Bristol-Myers Squibb, Genentech, Merck
Merrick Ross, MD – Advisory Board: GlaxoSmithKline, Merck; Speaker: Genomic Health Honorarium, GlaxoSmithKline
Aleksandar Sekulic, MD, PhD – Nothing to disclose
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Latha Shivakumar, PhD, CCMEP; Blair St. Amand; Jay Katz, CCMEP; CME Peer Review: Nothing to disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Jointly Sponsored By
This educational activity is supported by an educational grant from:
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.